placebo + linagliptin + background therapy
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Sep 30, 2016 โ Jan 18, 2019
NCT ID
NCT02897349About placebo + linagliptin + background therapy
placebo + linagliptin + background therapy is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT02897349. Target conditions include Diabetes Mellitus, Type 2.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02897349 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2